October 25, 2007
The FDA has granted marketing approval to Genzyme for its Renvela treatment for the control of serum phosphorus in patients with chronic kidney disease on dialysis. Renvela is a next-generation version of Renagel (sevelamer hydrochloride), the most-prescribed phosphate binder in the US. Genzyme expects to launch Renvela for dialysis patients in the US during the first quarter of 2008 and is pursuing regulatory approvals in Europe, South America and in other markets internationally. The company will continue to make Renagel available, with the long-term goal of transitioning patients to Renvela.